A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity
of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin
lymphoma.